hypoxanthine has been researched along with Ovarian Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Incalci, M; Erba, E; Sen, S; Sessa, C; Vikhanskaya, FL | 1 |
| Nagai, M; Nakamura, H; Olah, E; Prajda, N; Szekeres, T; Weber, G | 1 |
| Chan, TC; Howell, SB | 1 |
3 other study(ies) available for hypoxanthine and Ovarian Neoplasms
| Article | Year |
|---|---|
Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
Topics: Antineoplastic Agents; Cell Cycle; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Folic Acid; Folic Acid Antagonists; Humans; Hypoxanthine; Hypoxanthines; Leucovorin; Ovarian Neoplasms; Tetrahydrofolates; Thymidine; Time Factors; Tumor Cells, Cultured | 1994 |
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
Topics: Animals; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Hypoxanthine; Hypoxanthines; In Vitro Techniques; Methotrexate; Ovarian Neoplasms; Pancreatic Neoplasms; Rats; Thymidine; Thymidine Kinase; Tumor Cells, Cultured; Zidovudine | 1991 |
Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cyclic AMP; Dipyridamole; Drug Synergism; Female; Humans; Hypoxanthine; Hypoxanthines; Methotrexate; Ovarian Neoplasms; Thymidine | 1990 |